Cargando…
Stereotactic ablative radiotherapy for ultra-central lung tumors: prioritize target coverage or organs at risk?
BACKGROUND: Lung stereotactic ablative radiotherapy (SABR) is associated with low morbidity, however there is an increased risk of treatment-related toxicity in tumors directly abutting or invading the proximal bronchial tree, termed ‘ultra-central’ tumors. As there is no consensus regarding the opt...
Autores principales: | Murrell, Donna H., Laba, Joanna M., Erickson, Abigail, Millman, Barbara, Palma, David A., Louie, Alexander V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880025/ https://www.ncbi.nlm.nih.gov/pubmed/29606150 http://dx.doi.org/10.1186/s13014-018-1001-6 |
Ejemplares similares
-
Safety and Efficacy of Stereotactic Ablative Radiotherapy for Ultra-Central Lung Cancer
por: Wang, Bin, et al.
Publicado: (2022) -
Organizing pneumonia after stereotactic ablative radiotherapy of the lung
por: Murai, Taro, et al.
Publicado: (2012) -
Is lung stereotactic ablative radiotherapy safe after pneumonectomy?—a systematic review
por: Arifin, Andrew J., et al.
Publicado: (2020) -
A Review of Ongoing Trials of Stereotactic Ablative Radiotherapy for Oligometastatic Cancers: Where Will the Evidence Lead?
por: Al-Shafa, Faiez, et al.
Publicado: (2019) -
Stereotactic body radiotherapy for moderately central and ultra-central oligometastatic disease: Initial outcomes
por: Cooke, Rosie, et al.
Publicado: (2020)